card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

Learn more
English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

IND-Enabling Bundle of In Vitro Assays to Assess Drug-Drug Interaction Risk

DDI Fact Sheet
Home / Insights / IND-Enabling Bundle of In Vitro Assays to Assess Drug-Drug Interaction Risk

During development of new chemical entities (NCEs), an investigation into the likelihood of drug-drug interactions (DDI) is vital to the progression of these drug candidates. Possible drug-drug interactions can alter the pharmacokinetics of concomitantly administered medications, altering efficacy or toxicity. A definitive assessment of these risks should be performed early after selection of a lead candidate. Our scientists routinely evaluate these risks through validated, in vitro assays to determine the cytochrome P450 enzymes responsible for metabolism of NCEs and to assess the potential for NCEs to inhibit and/or induce these enzymes. These data will be included in the filing of the Investigational New Drug (IND) application to provide guideposts for clinical DDI assessments during the further development of drug candidates.

Contact us today to learn how we can help you determine any drug-drug interaction liability for your new drug/molecule.


Download Document